[.
]
Action/Kinetics:
Obtained from
Streptomyces rimosus forma paromomycina. Spectrum of activity resembles that of neomycin and kanamycin. Poorly absorbed from the GI tract and is ineffective against systemic infections when given PO.
Uses:
Inhibition of ammonia-forming bacteria in GI tract in hepatic encephalopathy, intestinal amebiasis, preoperative suppression of intestinal flora. Hepatic coma.
Investigational: Anthelmintic, to treat
Dientamoeba fragilis, Diphyllobothrium latum, Taenia saginata, T. solium, Dipylidium caninum and
Hymenolepis nana.
Contraindications:
Intestinal obstruction.
Special Concerns:
Use during pregnancy only if benefits outweigh risks. Use with caution in the presence of GI ulceration because of possible systemic absorption.
Additional Side Effects:
Diarrhea or loose stools. Heartburn, emesis, and pruritus ani. Superinfections, especially by monilia.
Drug Interactions:
Paromomycin inhibits penicillin.
How Supplied:
Capsule: 250 mg
Dosage
?Capsules
Hepatic coma.
Adults: 4 g/day in divided doses for 5-6 days.
Intestinal amebiasis.
Adults and children: 25-35 mg/kg/day administered in three doses with meals for 5-10 days.
D. fragilis
infections.
25-30 mg/kg/day in three divided doses for 1 week.
H. nana
infections.
45 mg/kg/day for 5-7 days.
D. latum, T. saginata, T. solium, D. caninum
infections.
Adults: 1 g/ q 15 min for a total of four doses;
pediatric: 11 mg/kg/15 min for four doses.
